Arutimol eye drops 0.25% 5ml

Mechanism of action

Non-selective beta-adrenoreceptor blocker without SMA. When applied topically reduces intraocular pressure, by reducing the formation of aqueous humor and a slight increase in its outflow. Reducing intraocular pressure does not affect the accommodation and pupil size, therefore there is no deterioration in visual acuity and the quality of color and night vision is not reduced. The effect appears 20 minutes after instillation, the maximum effect - in 1-2 hours; duration of action - 24 hours

After instillation of the eye drops in the moisture of the anterior chamber of the eye TCmax - 1-2 hours. The active substance enters the systemic circulation by absorption through the conjunctiva, the nasal mucosa and the lacrimal duct. Excretion of metabolites - by the kidneys. In newborns and young children, the concentration of the active substance significantly exceeds its Cmax in the plasma of adults.

Indications and usage

Open-angle glaucoma, secondary glaucoma (uveal, aphakic, post-traumatic, with a narrow angle of the anterior chamber of the eye and indications of a spontaneous or iatrogenic blockade of the opposite eye that was transferred in the past; as an additional miotichesky means: angle-glaucoma (in combination with myotics), acute intraocular elevation pressure, congenital glaucoma (with the ineffectiveness of other therapeutic measures).

Adults and children over 1 year old are instilled into the conjunctival sac with 1 drop of a 0.25% solution 2 times a day, with insufficient effectiveness, 1 drop of a 0.5% solution 2 times a day. With the normalization of intraocular pressure, the maintenance dose is 1 drop 0.25% once a day. The difference in the severity of the two concentrations is 10-15%.

Adverse reactions

Local reactions: irritation of the conjunctiva - conjunctival hyperemia, tearing or reduction of tearing, photophobia, swelling of the corneal epithelium, burning and itching in the eyes, eyelid hyperemia, short-term visual impairment; blepharitis, conjunctivitis, keratitis, with prolonged use may develop surface point keratopathy (decrease in the transparency of the cornea) and decrease the sensitivity of the cornea, possible ptosis, rarely - diplopia.Systemic reactions: paresthesia, rhinitis, nasal congestion, nasal bleeding, dizziness, decrease in blood pressure, collapse, bradycardia, bradyarrhythmia, AV blockade, reduction of myocardial contractility, aggravation of heart failure manifestations; headache, drowsiness, hallucinations, depression, muscle weakness, decreased potency; shortness of breath, bronchospasm, pulmonary insufficiency; nausea, vomiting, diarrhea, chest pain, tinnitus. Allergic reactions (including urticaria). Overdose. Symptoms: may develop general resorptive effects characteristic of beta-blockers (dizziness, headache, arrhythmia, bradycardia, bronchospasm, nausea, vomiting). Treatment: Immediately flush eyes with water or saline, symptomatic therapy.

Contraindications

Hypersensitivity, severe COPD (including bronchial asthma), sinus bradycardia, AV block II-III stage, heart failure II-III stage, cardiogenic shock, dystrophic processes in the cornea, atrophic rhinitis, pregnancy, lactation, childhood (up to 1 year). With care - pulmonary insufficiency, severe cerebrovascular insufficiency, chronic heart failure, diabetes mellitus, hypoglycemia, thyrotoxicosis, myasthenia gravis, the simultaneous appointment of other beta-blockers.

Special notes

Do not bury two beta-blockers in the eye at the same time. After instillation for 30 minutes, refrain from engaging in potentially hazardous activities requiring increased concentration and visual acuity. Care must be taken when driving a car at night, to limit the activities associated with the risk of poor lighting. Monitoring the effectiveness is recommended approximately 3-4 weeks after the start of therapy (no earlier than 1-2 weeks). With prolonged use of Timolol, a weakening effect is possible. When applied, it is necessary to control the function of tearing, the integrity of the cornea and to evaluate the size of the visual fields at least once every 6 months. At least once a month, measure intraocular pressure. The preservative contained in the preparation may be deposited on soft contact lenses, therefore, soft contact lenses should not be worn during treatment with the preparation.Hard contact lenses should be removed before instillation and wear no earlier than 15 minutes after it. When transferring patients to treatment with timolol, correction of refraction may be necessary after the effects of previously applied miotics have passed. In case of an upcoming surgery using general anesthesia, it is necessary to stop the drug within 48 hours.

Drug Interactions

Epinephrine, pilocarpine, systemic beta-blockers enhance the action. BMCC, sympatholytics, beta-blockers enhance arterial hypotension and bradycardia. Strengthens the action of muscle relaxants (timolol should be canceled 48 hours before the proposed general anesthesia using peripheral muscle relaxants).